Recruiting clinical trials in CH

Sotorasib (AMG 510)

Covalent KRASG12C inhibitor
Phase Ib/II
Combination
none (only outside of CH)
Indication
Tumor agnostic
CodeBreaK 100
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation
Amgen protocol ID 20170543
Status Switzerland
Main phase 2 study fully enrolled. New substudy currently recruiting NSCLC patients
Centers, Principal Investigators (PI):
USB, S. Rothschild
USZ, A. Curioni
HUG, A. Addeo

For patients that do not qualify for the CodeBreaK 100 trial, please contact Eva Vollenweider (evollenw@amgen.com) or Carine Bast (cepple@amgen.com) to evaluate further options (Named Patient Programme).
AMG 757

DLL3 x CD3 Half-life extended Bispecific T-Cell Engager
Phase II
Monotherapy
none
Indication
SCLC
A Phase 2 Study Evaluating Efficacy, Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Amgen protocol ID 20200491
Status Switzerland
Recruitment Start:
December 2021
Centers, PI:
HUG, A. Addeo
USZ, A. Curioni
AMG 757

DLL3 x CD3 Half-life extended Bispecific T-Cell Engager
Phase I
Combination
+/- Pembrolizumab
Indication
SCLC
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
Amgen protocol ID 20160323
Status Switzerland
Recruiting
Centers, PI:
CHUV, S. Peters
KSSG, M. Früh
T-VEC

Oncolytic Virus
Phase I/II
Combination
+ Pembrolizumab
Indication
BrCa (ER+, TNBC), CRC, HCC, BCC, CSCC
MASTERKEY-318
A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab
Amgen protocol ID 20140318
Status Switzerland
Recruiting
Centers, PI:
KSW, M. Pless
USZ, R. Fritsch
CHUV, A. Digklia
HUG, N. Mach
T-VEC

Oncolytic Virus
Phase I
Combination
none
Indication
Pediatric
A Phase 1, Multicenter, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non Central Nervous System Tumors That Are Amenable to Direct Injection
Amgen protocol ID 20110261
Status Switzerland
Recruiting
Centers, PI:
Universitäts-Kinderspital Zürich, N. Gerber
USB, T. Kühne

For further questions relating to the study programme, please contact Carine Bast or Eva Vollenweider